IMTX
Immatics N.V. trades as IMTX and has a market capitalization of $1.32 B, making it the #2449 largest US-listed company by market value. This page tracks Immatics N.V. through 220 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| 6-K | - | 2026-05-12 |
| 6-K | - | 2026-04-21 |
| 6-K | - | 2026-04-17 |
| New insider ownership | 3 | 2026-03-18 |
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting | Immatics N.V.
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer | Immatics N.V.
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting | Immatics N.V.
Immatics Announces First Quarter 2026 Financial Results and Business Update | Immatics N.V.
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting | Immatics N.V.
The largest companies sharing Immatics N.V.'s SEC industry classification (biological products, (no diagnostic substances)).
Immatics N.V. (IMTX) has a market capitalization of $1.32 B as of 2026-07-09, ranking #2449 among US-listed companies.